Clinical criteria for subtyping Parkinson's disease: Biomarkers and longitudinal progression

Brain

Volumn 140, Issue 7, 2017, Pages 1959-1976

  Fereshtehnejad, Seyed Mohammad ^a,b   Zeighami, Yashar ^c   Dagher, Alain ^c   Postuma, Ronald B ^a,d  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MCGILL UNIVERSITY   (Canada)

^d HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

biomarkers; neuroimaging; Parkinson's disease; prognosis; subtypes

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CLASSIFICATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC RISK; HUMAN; IMMUNOASSAY ANALYZER; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL; ATROPHY; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITIVE DEFECT; COMPLICATION; DOPAMINERGIC NERVE CELL; DYSAUTONOMIA; MIDDLE AGED; MULTICENTER STUDY; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PARASOMNIA; PATHOLOGY; PROSPECTIVE STUDY;

AMYLOID BETA-PEPTIDES; ATROPHY; BIOMARKERS; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; DOPAMINERGIC NEURONS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PRIMARY DYSAUTONOMIAS; PROSPECTIVE STUDIES; REM SLEEP BEHAVIOR DISORDER; TAU PROTEINS;

EID: 85022320174     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awx118     Document Type: Article

References (41)

1. Benton AL, Varney NR, Hamsher KD. Visuospatial judgment. A clinical test. Arch Neurol 1978; 35: 364-7
2. Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, et al. Time to redefine PD? Introductory statement of the MDS task force on the definition of Parkinson's disease. Mov Disord 2014; 29: 454-62
3. Boeve BF, Silber MH, Ferman TJ, Lin SC, Benarroch EE, Schmeichel AM, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med 2013; 14: 754-62
4. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211
5. Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania smell identification test: a rapid quantitative olfactory function test for the clinic. Laryngoscope 1984; 94 (2 Pt 1): 176-8
6. Erro R, Picillo M, Vitale C, Palladino R, Amboni M, Moccia M, et al. Clinical clusters and dopaminergic dysfunction in de-novo Parkinson disease. Parkinsonism Relat Disord 2016; 28: 137-40
7. Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 2015; 72: 863-73
8. Formann AK. Die latent-class-analyse: einfuührung in die theorie und anwendung. Weinheim: Beltz; 1984
9. Gladsjo JA, Schuman CC, Evans JD, Peavy GM, Miller SW, Heaton RK. Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment 1999; 6: 147-78
10. Gomperts SN, Locascio JJ, Rentz D, Santarlasci A, Marquie M, Johnson KA, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013; 80: 85-91
11. Graham JM, Sagar HJ. A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes. Mov Disord 1999; 14: 10-20
12. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008; 115: 409-15
13. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008; 79: 368-76
14. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-5
15. Kang JH, Irwin DJ, Chen-Plotkin AS, Siderowf A, Caspell C, Coffey CS, et al. Association of cerebrospinal fluid beta-amyloid 1-42, Ttau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol 2013; 70: 1277-87
16. Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's progression markers initiative study. Acta Neuropathol 2016; 131: 935-49
17. Kim JS, Oh YS, Lee KS, Kim YI, Yang DW, Goldstein DS. Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology 2012; 79: 1323-31
18. McMillan CT, Wolk DA. Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease. J Neurol Neurosurg Psychiatry 2016; 87: 1112-22
19. Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, et al. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurol 2015; 14: 1002-9
20. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695-9
21. Parkinson Progression Marker Initiative. The Parkinson progression marker initiative (PPMI). Prog Neurobiol 2011; 95: 629-35
22. Postuma RB, Adler CH, Dugger BN, Hentz JG, Shill HA, Driver-Dunckley E, et al. REM sleep behavior disorder and neuropathology in Parkinson's disease. Mov Disord 2015; 30: 1413-17
23. Postuma RB, Gagnon JF, Vendette M, Charland K, Montplaisir J. Manifestations of Parkinson disease differ in association with REM sleep behavior disorder. Mov Disord 2008; 23: 1665-72
24. Postuma RB, Gagnon JF, Vendette M, Montplaisir JY. Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease. Brain 2009; 132 (Pt 12): 3298-307
25. Rolinski M, Szewczyk-Krolikowski K, Tomlinson PR, Nithi K, Talbot K, Ben-Shlomo Y, et al. REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson's disease. J Neurol NeurosurgPsychiatry 2014; 85: 560-6
26. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, Starkstein S, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007; 22: 1077-92
27. Shapiro AM, Benedict RH, Schretlen D, Brandt J. Construct and concurrent validity of the Hopkins verbal learning test-revised. Clin Neuropsychol 1999; 13: 348-58
28. Sieber BA, Landis S, Koroshetz W, Bateman R, Siderowf A, Galpern WR, et al. Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's disease 2014 conference. Ann Neurol 2014; 76: 469-72
29. Smith A. Symbol digit modalities test. Los Angeles, CA: Western Psychological Services; 1991
30. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the state-trait anxiety inventory. Palo Alto, CA: Consulting Psychologists Press; 1983
31. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord 2013; 28: 668-70
32. Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire- A new diagnostic instrument. Mov Disord 2007; 22: 2386-93
33. van Rooden SM, Colas F, Martinez-Martin P, Visser M, Verbaan D, Marinus J, et al. Clinical subtypes of Parkinson's disease. Mov Disord 2011; 26: 51-8
34. van Rooden SM, Heiser WJ, Kok JN, Verbaan D, van Hilten JJ, Marinus J. The identification of Parkinson's disease subtypes using cluster analysis: a systematic review. Mov Disord 2010; 25: 969-78
35. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ 2001; 323: 1123-4
36. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord 2004; 19: 1306-12
37. Wechsler D. Wechsler adult intelligence scale. . San Antonio, TX: Psychological Corporation; 2008
38. Weintraub D, Hoops S, Shea JA, Lyons KE, Pahwa R, Driver-Dunckley ED, et al. Validation of the questionnaire for impulsivecompulsive disorders in Parkinson's disease. Mov Disord 2009; 24: 1461-7
39. Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord 2015; 30: 919-27
40. Yesavage JA, Sheikh JI. 9/Geriatric Depression Scale (GDS). Clin Gerontol 1986; 5: 165-73
41. Zeighami Y, Ulla M, Iturria-Medina Y, Dadar M, Zhang Y, Larcher KM, et al. Network structure of brain atrophy in de novo Parkinson's disease. Elife 2015; 4